|
Neose Technologies Initiates Phase I Trial of NE-180 |
|
|
|
14 Feb 2006 |
Announced that is has begun dosing healthy volunteers in a Phase I clinical trial of NE-180, the company's long-acting, GlycoPEGylated erythropoietin for the treatment of anemia.
HORSHAM, PA, USA | Feb. 13, 2006 | Neose Technologies, Inc. (NasdaqNM:NTEC) today announced that is has begun dosing healthy volunteers in a Phase I clinical trial of NE-180, the company's long-acting, GlycoPEGylated erythropoietin for the treatment of anemia. The trial, which is being conducted in Western Europe, will evaluate the safety and pharmacokinetics of NE-180 in approximately forty volunteers. The Phase I trial is designed as an open-label, single ascending dose study that will evaluate both subcutaneous and intravenous administration of NE-180. If the trial results demonstrate that single ascending doses are safe and well tolerated, the Company expects to commence a multiple dose Phase IIa trial in the second half of 2006.
"The initiation of dosing in our Phase I trial for NE-180 marks an important milestone for Neose. NE-180 is the first of the Company's long-acting therapeutic proteins to enter clinical development, and we are hopeful that the human data generated by this trial will further validate our unique expertise in developing improved versions of therapeutic proteins," said George J. Vergis, Ph.D., Neose president and chief operating officer.
About Neose Technologies, Inc.
Neose is a biopharmaceutical company using its proprietary enzymatic technologies to develop improved drugs, focusing primarily on therapeutic proteins. Neose uses its GlycoAdvance(R) and GlycoPEGylation(TM) technologies to develop improved versions of drugs with proven safety and efficacy. Neose intends to apply its technologies to products it is developing on its own and to products it co-develops and co-owns with others. It also expects to make its technologies available, through strategic partnerships, to improve the products of other parties. Neose's first two proprietary candidates are NE-180 (GlycoPEG-EPO), a long-acting version of erythropoietin, and GlycoPEG-GCSF, a long-acting version of granulocyte colony stimulating factor (G-CSF).
For more information, please visit www.neose.com.
Neose "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that NE-180 fails in clinical trials, the risk that we will never receive regulatory approval of NE-180 and the risk that we will be unable to successfully commercialize or market NE-180. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of Neose's Annual Report on Form 10-K for the year ended December 31, 2004, entitled "Factors Affecting the Company's Prospects" and discussions of potential risks and uncertainties in Neose's subsequent filings with the SEC.
CONTACT: Neose Technologies, Inc.
A. Brian Davis, 215-315-9000
or
Investor Relations:
Barbara Krauter, 215-315-9004
SOURCE: Neose Technologies, Inc. |
